| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KRT18 |
| Uniprot No | P05783 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-430aa |
| 氨基酸序列 | SFTTRSTFSTNYRSLGSVQAPSYGARPVSSAASVYAGAGGSGSRISVSRSTSFRGGMGSGGLATGIAGGLAGMGGIQNEKETMQSLNDRLASYLDRVRSLETENRRLESKIREHLEKKGPQVRDWSHYFKIIEDLRAQIFANTVDNARIVLQIDNARLAADDFRVKYETELAMRQSVENDIHGLRKVIDDTNITRLQLETEIEALKEELLFMKKNHEEEVKGLQAQIASSGLTVEVDAPKSQDLAKIMADIRAQYDELARKNREELDKYWSQQIEESTTVVTTQSAEVGAAETTLTELRRTVQSLEIDLDSMRNLKASLENSLREVEARYALQMEQLNGILLHLESELAQTRAEGQRQAQEYEALLNIKVKLEAEIATYRRLLEDGEDFNLGDALDSSNSMQTIQKTTTRRIVDGKVVSETNDTKVLRH |
| 预测分子量 | 48.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KRT18重组蛋白的3篇参考文献示例(注：内容为模拟概括，非真实文献)：
1. **文献名称**：*Expression and Purification of Recombinant Human KRT18 in Escherichia coli for Antibody Production*
**作者**：Smith J, et al.
**摘要**：研究通过大肠杆菌表达系统成功表达并纯化了带有His标签的重组KRT18蛋白，优化了诱导条件以提高溶解度。该蛋白被用作抗原，制备了特异性抗体，验证了其在免疫印迹中对肝癌细胞裂解物的识别能力。
2. **文献名称**：*KRT18 Phosphorylation as a Biomarker of Epithelial-Mesenchymal Transition in Breast Cancer*
**作者**：Lee S, et al.
**摘要**：利用哺乳动物细胞表达的重组KRT18蛋白，研究其在乳腺癌细胞上皮-间质转化(EMT)中的磷酸化修饰。发现Ser52位点的磷酸化与肿瘤转移相关，提示其作为预后标志物的潜力。
3. **文献名称**：*Development of a KRT18-Based ELISA for Early Detection of Liver Fibrosis*
**作者**：Zhang Y, et al.
**摘要**：通过重组KRT18蛋白建立了一种高灵敏度的ELISA检测方法，用于量化血清中KRT18片段(如CYFRA 21-1)。临床样本分析显示，该方法对肝纤维化早期诊断具有较高特异性。
4. **文献名称**：*Recombinant KRT18 Binds to Chemotherapeutic Agents: Implications for Drug Resistance*
**作者**：Wang H, et al.
**摘要**：研究发现，通过体外表达的重组KRT18蛋白能够与紫杉醇等化疗药物结合，可能通过调控细胞骨架稳定性影响癌细胞耐药性，为克服耐药机制提供了新思路。
(注：以上文献信息为虚构，仅作格式参考。实际研究中请通过PubMed或专业数据库检索真实文献。)
Keratin 18 (KRT18), a member of the intermediate filament protein family, is primarily expressed in epithelial cells, particularly simple epithelial and glandular tissues. As a type I acidic keratin, it pairs with type II keratins (e.g., KRT8) to form dynamic cytoskeletal networks, providing mechanical stability and regulating cellular processes like stress response, apoptosis, and signaling. The human KRT18 gene encodes a 430-amino-acid protein with conserved structural domains: an N-terminal globular head, a central α-helical rod, and a C-terminal tail.
Recombinant KRT18 protein is produced via genetic engineering, often using bacterial (E. coli) or mammalian expression systems, followed by purification to ensure homogeneity. This engineered protein retains native structural and functional properties, making it valuable for research and diagnostics.
KRT18 has emerged as a biomarker in multiple pathologies. In cancer, its overexpression or abnormal phosphorylation is linked to tumor progression (e.g., breast, colorectal cancers). During apoptosis, caspase-cleaved KRT18 fragments are released into circulation, serving as indicators of epithelial cell death. In liver diseases, such as non-alcoholic steatohepatitis (NASH), serum KRT18 fragments correlate with disease severity.
Research applications include studying epithelial cell biology, drug toxicity screening, and exploring cell death mechanisms. Clinically, recombinant KRT18 aids in developing diagnostic assays (e.g., ELISA for detecting disease-specific fragments) and validating therapeutic targets. Mutations in KRT18 are associated with cryptogenic cirrhosis and other disorders, underscoring its role in cellular integrity.
Overall, recombinant KRT18 is a critical tool bridging basic research and clinical innovation, with implications for understanding epithelial pathologies and advancing precision medicine.
×
